Abu Dhabi Biobank And AstraZeneca Drive Precision Medicine In The Middle East

Abu Dhabi Biobank, a joint initiative of the Department of Health Abu Dhabi and M42, has entered a collaboration with AstraZeneca to advance precision medicine and clinical research translation. The agreement aims to convert complex biological data into practical treatments, supporting more tailored care for patients in the Middle East and wider regions.

The collaboration is positioned as a major step in Abu Dhabi’s plan to strengthen its role in global biomedical research and life sciences. By linking population-based data with clinical outcomes, the project is expected to speed movement from scientific discovery to regulatory approval and everyday medical use across key disease areas.

At the core of the partnership, Abu Dhabi Biobank’s large biospecimen collection, genomic resources and research infrastructure will be combined with AstraZeneca’s scientific expertise. AstraZeneca brings experience across cardiovascular, renal, metabolic, respiratory, immunology and oncology therapies, enabling deeper studies that can support new diagnostics, treatment approaches and prevention strategies.

Both organisations intend to work together across several strategic pillars that link discovery and delivery. The focus includes clinical development, precision medicine programmes and real-world evidence generation. These activities will advance biomarker research, pharmacogenomics and patient stratification, while also addressing health economics, regulatory science, digital health tools and AI-driven analytics.

Commenting on the collaboration, Albarah ElKhani, Chief Operating Officer, Integrated Health Solutions, M42, said, "This collaboration represents more than a partnership; it is a shared vision to shape the future of medicine. By combining Abu Dhabi Biobank’s deep population insights and AstraZeneca’s scientific leadership, we are laying the foundation for breakthroughs that can redefine how diseases are understood, prevented and treated, particularly within the Middle Eastern population."

The partners plan to draw on longitudinal cohort data and population-specific information to improve understanding of disease patterns in the region. This approach is expected to support earlier detection, better prevention and more personalised treatment pathways, especially for conditions that show different behaviour across diverse communities and risk groups.

Abu Dhabi Biobank and AstraZeneca precision medicine partnership for regional patients

Sameh ElFangary, Country President, Gulf and Pakistan, AstraZeneca, said, "Precision medicine can only succeed when it reflects the diversity of the world’s populations. Through our partnership with Abu Dhabi Biobank, we are combining world-class science with local data to enable earlier identification of at-risk patients particularly in rare and difficult-to-diagnose diseases and to help shape more personalised care pathways for the future. This collaboration marks an important step toward advancing equitable and data-driven healthcare for patients across our region and beyond."

By using Abu Dhabi Biobank’s diverse, high-quality biospecimens and datasets, paired with AstraZeneca’s strength in translational and clinical research, the collaboration aims to generate medical insights that are locally relevant yet globally useful. The model highlights how shared science and structured data can support better outcomes for patients in the UAE, the wider Middle East and internationally.

With inputs from WAM